Design Therapeutics Inc [DSGN] stock is trading at $10.62, up 11.20%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DSGN shares have gain 8.37% over the last week, with a monthly amount glided 9.71%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Design Therapeutics Inc [NASDAQ: DSGN] stock has seen the most recent analyst activity on January 07, 2026, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $18. Previously, Leerink Partners upgraded its rating to Outperform on December 03, 2025, and kept the price target unchanged to $14. On December 03, 2025, Craig Hallum initiated with a Buy rating and assigned a price target of $15 on the stock. RBC Capital Mkts upgraded its rating to an Outperform but stick to its price target of $13 on November 20, 2025. Piper Sandler upgraded its rating to an Overweight and raised its price target to $12 on May 07, 2024. Piper Sandler downgraded its rating to Neutral for this stock on November 14, 2023, and downed its price target to $6. In a note dated August 15, 2023, Wedbush downgraded a Neutral rating on this stock and revised its target price from $19 to $6.
Design Therapeutics Inc [DSGN] stock has fluctuated between $2.60 and $10.31 over the past year. Currently, Wall Street analysts expect the stock to reach $15.67 within the next 12 months. Design Therapeutics Inc [NASDAQ: DSGN] shares were valued at $10.62 at the most recent close of the market. An investor can expect a potential return of 47.55% based on the average DSGN price forecast.
Analyzing the DSGN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.31 and Total Capital is -0.39. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Design Therapeutics Inc’s Current Ratio is 18.71. As well, the Quick Ratio is 18.71, while the Cash Ratio is 1.35.
Transactions by insiders
Recent insider trading involved Logos Global Master Fund LP, Director, that happened on Nov 18 ’25 when 0.12 million shares were purchased. Director, Logos Global Master Fund LP completed a deal on Nov 14 ’25 to buy 0.62 million shares. Meanwhile, Director Logos Global Master Fund LP bought 0.41 million shares on Nov 07 ’25.
